Pharma Focus America

BenevolentAI and AstraZeneca Continue to Progress Novel Target Into Portfolio

Wednesday, June 26, 2024

BenevolentAI (Euronext Amsterdam: BAI), a leader in applying advanced AI to biopharma drug discovery, has announced a significant milestone in its partnership with AstraZeneca. Together, they have identified a novel target for systemic lupus erythematosus (SLE) to be added to AstraZeneca's research portfolio.

This achievement marks the second target chosen this year as part of their extended collaboration, demonstrating ongoing progress in target identification. The newly discovered SLE target, validated through BenevolentAI's AI-driven drug discovery platform and experimental validation by AstraZeneca, builds on their partnership initiated in 2019 focusing on idiopathic pulmonary fibrosis and chronic kidney disease, and expanded in 2022 to include heart failure and SLE.

The collaboration leverages AstraZeneca's disease-specific expertise alongside BenevolentAI's biomedical knowledge and advanced AI technology. It includes upfront payments, research funding, and potential milestones and royalties on future product sales.

SLE, a chronic autoimmune disease affecting mainly women and certain ethnic groups, involves the immune system attacking the body's own tissues, causing inflammation and organ damage. The discovery of this new target holds promise for developing therapies aimed at improving the lives of SLE patients.

BenevolentAI, expressed optimism about the collaboration's potential to introduce new therapeutic options for SLE patients. AstraZeneca's Prof. Maria Belvisi reaffirmed their commitment to advancing lupus treatments through innovative research and patient-focused insights.

This collaboration underscores the role of AI-driven platforms in accelerating the discovery of potential treatments across diverse therapeutic areas.

 

Source: businesswire.com

Thermo Fisher Scientific - mRNA ServicesFuture Labs Live USA 2024World Vaccine Congress Europe 2024World Orphan Drug Congress 2024Advanced Therapies USA 2024World Orphan Drug Congress Europe 2024